Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 6;94(5):e480. doi: 10.1097/MD.0000000000000480

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0

PMC Copyright notice

Changes in serum enzyme. The ALT and AST (reflects the hepatocyte injury) were high at first and decreased after treatment, while GGT (reflects cholestasis) were not high but gradually increased within 2 months. It is in accordance with the characteristics of FCH. Changes in prothrombin and plasma albumin. These two indicators reflect the liver synthetic function, their alterations were similar to those in figure C, which show the liver metabolic function. Changes in plasma bilirubin. From day 42 to 98, the patients showed severe cholestasis and the BIL curve ascended sharply. There were several drop-downs on the peak due to plasmapheresis. The curve descended remarkably after the liver function began to benefit from the treatment.